Home › Research › Answers › Blood pressure and dementia
Blood pressure, hypertension and dementia: what the studies report
High blood pressure in midlife is one of the best-established risk factors for later dementia, and treating it is one of the few preventive measures tested in large trials. This page shows what the library holds.
- 1,117studies in the library match, of 29,780
- 181name it in the title
- 1964–2026years published
- 1,077peer-reviewed articles
The query: title or abstract mentions "hypertension"/"hypertensive", "blood pressure", "antihypertensive" or "systolic", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,780 study records, as of 2026-11-09. Every count on this page comes from that match. The matched list as JSON.
Sustained high blood pressure damages the small vessels of the brain, causes silent strokes and white-matter changes, and is linked to Alzheimer's pathology as well as vascular dementia. The relationship changes with age: high pressure in midlife raises later risk, while in very old age falling blood pressure can be a sign of illness already under way.
Large randomised trials of blood-pressure-lowering drugs have measured dementia or cognitive impairment as an outcome, which makes this one of the few risk factors with trial evidence rather than only observational data.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 1,117 matched records are quoted; each links to its study page and from there to the paper.
“Intervention effects were particularly due to improvements in diet (odds ratio [OR]: 1.60, 95% CI: 1.16, 2.22) and hypertension (OR: 1.61, 95% CI: 1.19, 2.18).”
“Over 48 months, the net reduction in systolic BP was 22.0 mm Hg (95% confidence interval (CI) 20.6 to 23.4; P < 0.0001) and that in diastolic BP was 9.3 mm Hg (95% CI 8.7 to 10.0; P < 0.0001) in the intervention group compared to usual care.”
“The most common AEs considered related to treatment were mild, transient changes in blood pressure in the GRF6019 group (hypotension: 2 patients [11.1%]; hypertension: 1 patient [5.6%]); there were no related AEs in the placebo group.”
“Approximately 30%-40% of dementia cases have been estimated to be attributed to modifiable risk factors, including hypertension, smoking and sedentary lifestyle.”
“Multilevel logistic regression reported an adjusted odds ratio 0.87 (95% confidence interval: 0.75, 0.99) in favour of antihypertensive treatment reducing risk of incident dementia with a mean BP lowering of 10/4 mmHg.”
“Novel VaD loci were associated with hypertension, diabetes, and neuron maintenance (SPRY2, FOXA2, AJAP1, and PSMA3).”
“Clusters with diffuse or frontal-predominant cortical thinning, but with more favourable vascular profiles, characterized by lower blood pressure and reduced obesity, showed significantly less cortical thinning (mean thickness, AD-signature, and resilience-signature regions; all p < 0.05) following the intervention.”
“Participants with untreated hypertension had a 36% (hazard ratio [HR] 1.36, 95% CI 1.01-1.83, p = 0.0406) and 42% (HR 1.42, 95% CI 1.08-1.87, p = 0.0135) increased risk of AD compared with "healthy controls" and those with treated hypertension, respectively.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 76 |
| Randomised controlled trial | 29 |
| Other clinical trial | 12 |
| Cohort or longitudinal study | 200 |
| Case-control study | 15 |
| Cross-sectional study | 72 |
| Other recorded design | 12 |
| No design recorded | 701 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 70 | |
| 2025 | 183 | |
| 2024 | 43 | |
| 2023 | 52 | |
| 2022 | 56 | |
| 2021 | 66 | |
| 2020 | 63 | |
| 2019 | 60 | |
| 2018 | 49 | |
| 2017 | 35 | |
| 2016 and earlier | 439 |
Other counts within the matched set
| Peer-reviewed articles | 1,077 |
| Marked open access in the record | 390 |
| Rated "high" evidence strength in alzhub's summary | 179 |
| Rated "moderate" evidence strength in alzhub's summary | 307 |
| Rated "low" evidence strength in alzhub's summary | 624 |
| No evidence-strength rating | 7 |
| Records stating a participant count | 486 |
| Median participants (those records) | 992 |
| Largest participant count | 2,577,000 |
Within the 1,117 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that mention antihypertensive treatment | 107 | the abstract also contains "antihypertensive", "blood pressure lowering" or "intensive blood pressure" |
| …about midlife blood pressure | 125 | the abstract also contains "midlife" or "middle age" |
| …that are randomised trials or mention one | 124 | the abstract also contains "randomised" or "placebo" |
| …that report a hazard ratio | 114 | the abstract also contains "hazard ratio" or "HR" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis
- Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial
- Association of the Mediterranean Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet With the Risk of Dementia
- Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis
- Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis
- Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
- The Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet for the Aging Brain: A Systematic Review
- Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet and Cognitive Function and its Decline: A Prospective Study and Meta-analysis of Cohort Studies
- Hypertension is a potential risk factor for vascular dementia: systematic review
- Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study
Systematic reviews and meta-analyses in the set
76 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Metabolic Syndrome and the Risk of Alzheimer's Disease: A Meta-Analysis
- Western diet is associated with a smaller hippocampus: a longitudinal investigation
- Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias
- Potentially Modifiable Risk Factors for Dementia and Mild Cognitive Impairment: An Umbrella Review and Meta-Analysis
- UK Biobank: opportunities for cardiovascular research
Newest matched studies
- Retinal biomarkers and dementia risk: A review of evidence across the 14 Lancet modifiable risk factors for dementia
- Location-specific Longitudinal Patterns of Subcortical and Lobar Cerebral Microhemorrhages in Preclinical Alzheimer Disease
- Oligodendrocyte stress response as a driver of vascular dementia
- Visit-to-Visit Blood Pressure Variability, Glycemic Status and the Risk of Dementia, Stroke, and All-Cause Mortality: A UK Biobank Cohort Study
- Disease-Specific Perturbational Convergence Between Genetic-Risk and Disease-State Transcriptomic Signatures in Alzheimer's Disease
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Neurology | 61 |
| Alzheimer s & Dementia | 32 |
| Journal of Alzheimer's disease : JAD | 29 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 27 |
| Stroke | 26 |
Questions
- Does treating high blood pressure prevent dementia?
- Randomised trials of blood-pressure lowering have measured cognitive outcomes, and some report fewer cases of cognitive impairment in the intensively treated group. The quoted papers give the trial results and the cohort figures behind the midlife link.
- How many studies on blood pressure and dementia does alzhub hold?
- 1,117 of the 29,780 study records in alzhub's library match the query "title or abstract mentions "hypertension"/"hypertensive", "blood pressure", "antihypertensive" or "systolic""; 181 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 76 systematic review or meta-analysis, 29 randomised controlled trials, 12 other clinical trials, 200 cohort or longitudinal studys, 15 case-control studys, 72 cross-sectional studys; 701 record no design.
- What is the most recent study in the set?
- "Retinal biomarkers and dementia risk: A review of evidence across the 14 Lancet modifiable risk factors for dementia" (PsyArXiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Neurology (61); Alzheimer s & Dementia (32); Journal of Alzheimer's disease : JAD (29), counted across the matched records.
Read on
- Vascular dementiaThe dementia high blood pressure most directly causes.
- PreventionWhat has been properly tested.
- Risk factors, rankedBlood pressure among the modifiable risks.